FluoGuide A/S
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a FLUO.ST research report →
Companyfluoguide.com
FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology.
- CEO
- Morten Albrechtsen
- IPO
- 2019
- Employees
- 7
- HQ
- Copenhagen, DK
Price Chart
Valuation
- Market Cap
- $565.13M
- P/E
- -10.73
- P/S
- 6828.10
- P/B
- 7.79
- EV/EBITDA
- -9.35
- Div Yield
- 0.00%
Profitability
- Gross Margin
- -139.65%
- Op Margin
- -69959.64%
- Net Margin
- -69500.20%
- ROE
- -218.15%
- ROIC
- -42.13%
Growth & Income
- Revenue
- $0 · -100.00%
- Net Income
- $-40,390,651 · -39.48%
- EPS
- $-2.87 · -28.70%
- Op Income
- $-40,987,416
- FCF YoY
- -26.09%
Performance & Tape
- 52W High
- $47.60
- 52W Low
- $28.00
- 50D MA
- $39.74
- 200D MA
- $38.41
- Beta
- 0.42
- Avg Volume
- 7.87K
Get TickerSpark's AI analysis on FLUO.ST
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our FLUO.ST Coverage
We haven't published any research on FLUO.ST yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate FLUO.ST Report →